We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Method Creates Proteins for Drug Development

By Biotechdaily staff writers
Posted on 03 Oct 2005
Biochemists have discovered a process by which a simple organism can generate 10 trillion varieties of a single protein, a finding that may provide a new way to develop new drugs.

Scientists from the University of California, San Diego (UCSD; USA) describe in the October 2005 issue of the journal Nature Structural and Molecular Biology, the mechanism by which a virus that infects bacteria, called a bacteriophage (or phage), can produce an array of variants of a specific protein. More...


Because this level of protein diversity is very rare, recreating the process in the laboratory could give investigators a new tool to create therapeutic enzymes, vaccines, and other medically significant proteins. This is only the second type of massively variable protein ever discovered, explained Dr. Partho Ghosh, a professor of chemistry and biochemistry at UCSD who headed the research team.

Only antibodies have more variation than this protein in phage. However, the genetic mechanism used by the phage to generate this diversity is completely different from that used by animals to produce antibodies, and has the advantage of giving the protein greater stability. If we can learn from these organisms how to set up a system that churns out proteins with enormous variability, it may be possible to target these new proteins to specific cells to treat disease, said Stephen McMahon, a former postdoctoral fellow in Dr. Ghosh's. This idea has already been picked up by the biotech industry.

The task of the greatly variable phage protein is to attach the phage to the bacteria they infect. The phage predator protein fits into a prey protein on the bacteria like a three-dimensional puzzle piece. However, bacteria are constantly changing the proteins on their surface. To keep up with the erratic alterations in the prey protein, the phage must generate many different predator proteins for at least one to have a satisfactory fit.

In their article, the USCD investigators reported how by changing the amino acids at one or more of just 12 sites on the predator protein, the phage are able to generate 10 trillion proteins, each with the potential to bind to a different prey protein. This variability happens as DNA is being copied into the RNA blueprint for the protein. The sequence of DNA bases at the 12 sites has novel features that cause frequent errors to be made in the copying process. As a result, the RNA ends up specifying a different amino acid, and a protein with different structural and chemical characteristics is produced.

Antibodies are another kind of predator protein that must react to quickly evolving prey proteins, because microorganisms are continually changing proteins on their surfaces to elude the immune system. Dissimilar from the phage protein, antibodies have a complex loop structure. The size of the loops differs in addition to the amino acid building blocks that make up the antibody protein. Even though this process can generate more than 100 trillion different antibodies, the scientists stated that replicating it in a test tube would be very difficult because the loops would have the propensity to fold improperly.

Because of its stability, the phage protein makes a better model to create protein diversity in a test tube, explained Jason Miller, a graduate student in Dr. Ghosh's lab who performed much of the research. Our discovery shows that nature has provided at least two completely different methods to generate a huge amount of protein variability, and it opens up a whole new platform for protein development.



Related Links:
University of California, San Diego

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.